---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-016110"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2022-04-27T23:59:59+00:00"
generated_at: "2026-06-26T04:07:32.485622+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Viking Q1 2022 net loss $16.1M; VK2809 enrollment continues, VK2735 Phase 1 ongoing

## Summary
- Net loss $16.1M ($0.21/share) vs $14.0M ($0.19/share) in Q1 2021; R&D up to $12.6M.
- Cash and investments $184.9M at March 31, 2022, down from $202.1M at Dec 31, 2021.
- Phase 2b VOYAGE study of VK2809 for NASH expects to complete enrollment in 2H22.
- Phase 1 trial of dual GLP-1/GIP agonist VK2735 ongoing; results expected by year-end.
- VK0214 for X-ALD on clinical hold, expects to submit requested preclinical data to FDA in 2Q22.

## SEC filing metadata
- accession: 0001564590-22-016110
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2022-04-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000156459022016110/0001564590-22-016110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000156459022016110/vktx-8k_20220427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-016110
- JSON: https://secwatch.observer/filing/0001564590-22-016110.json
- Plain text: https://secwatch.observer/filing/0001564590-22-016110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.